1. Roche's MS Drug Fenebrutinib Faces Regulatory Hurdle as Liver Safety Signals, Patient Deaths Emerge
Roche is pushing its experimental multiple sclerosis drug fenebrutinib toward regulators, but its path is shadowed by unresolved safety concerns. The Swiss pharmaceutical giant presented new data this week, aiming to prove the drug's efficacy in reducing relapse rates and slowing disability progression. However, the su...